Trump signs order to fast‑track ibogaine research
SkimNews Take
Trump's executive order on psychedelics, while framed around specific treatments, signals a broader shift in federal drug policy, potentially paving the way for wider acceptance and research beyond the initial scope.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- President Trump signed an executive order to fast‑track research and access to psychedelic drugs for mental‑health treatments.
- Ibogaine, a drug from a West African shrub, is highlighted in the order for its promise to relieve long‑term effects of traumatic brain injury.
- Joe Rogan’s role in the story is examined on the podcast.
- Madeleine Finlay interviews journalist Mattha Busby about the policy shift and its impact on scientists and researchers.
Why it matters: Mental‑health patients and biotech firms gain faster access to psychedelic therapies; researchers must adapt to new regulatory pathways, accelerating clinical trials and reducing development costs.
